Shire
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Shire sits in the top decile of US sponsors by registered trial count (#133 of 15,742 sponsors by registered trial count).
Shire: 245 sponsored US clinical trials, 1 recruiting.
Shire sponsors 245 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 212 completed. 118 of these trials are in Phase 3-4 (later-stage) and 108 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 6 trials.
Top-decile sponsor footprint
Shire ranks in the top decile of sponsors by registered trial count (#133 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
212 of 242 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
245 total, page 4 of 5
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administration
NCT01095497
CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12
NCT01095510
Safety and Efficacy of SPD489 on Executive Function Behaviors in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT01101022
Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)
NCT01081145
Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® in Adult Patients With Fabry Disease
NCT01124643
Pharmacodynamic Profile of SPD489 in Healthy Adult Males Undergoing a Nocturnal Period of Acute Sleep Loss
NCT01096680
A Study of Patients With Sanfilippo Syndrome Type A (MPS IIIA)
NCT01047306
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
NCT01059526
Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
NCT01010750
A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®
NCT00920647
Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)
NCT00997984
SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder
NCT00985725
Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)
NCT00930644
Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms
NCT00922272
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE
NCT00914966
A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye Conducted in a Controlled Adverse Environment (CAE)
NCT00926185
FST-201 In The Treatment of Acute Fungal Otitis Externa
NCT00945646
FST-201 In The Treatment of Acute Otitis Externa
NCT00945802
Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant
NCT00905424
A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)
NCT00912093
Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase®
NCT00937794
FST-100 Ophthalmic Suspension in Acute Adenoviral Conjunctivitis
NCT00941486
A Drug Interaction Study of SPD503 and Vyvanse Administered Alone and In Combination in Normal Healthy Volunteers
NCT00919867
The Pharmacokinetics of Rocaltrol When Administered Alone or in Combination With Fosrenol or Renvela in Healthy Volunteers
NCT00925704
A Drug Interaction Study of SPD503 and Concerta Administered Alone and In Combination in Normal Healthy Volunteers
NCT00901576
Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder
NCT00877487
Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis
NCT00882687
Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers
NCT00875017
Pharmacodynamic Study of Two Lanthanum Carbonate Formulations in Healthy Adults
NCT00880750
Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17
NCT00784654
Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis
NCT00762073
Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease
NCT00864851
Use of NPSP558 in the Treatment of Hypoparathyroidism
NCT00732615
Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects
NCT00798967
Compare Subjective Drug Liking & Pharmacokinetics of Vyvanse™ and ADDERALL XR® When Administered as an Oral Solution
NCT00776555
Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study
NCT00764868
An Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients
NCT00882921
Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT00735371
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
NCT00746733
Efficacy and Safety of SPD503 in Combination With Psychostimulants
NCT00734578
Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
NCT00697515
Guanfacine Immediate-release Electrocardiogram Results (QTc) Study
NCT00672984
An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease
NCT00635427
Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease
NCT00553631
Prevention of Recurrence of Diverticulitis
NCT00545103
Prevention of Recurrence of Diverticulitis
NCT00545740
Pharmacokinetics (PK) of 20 mg Teduglutide in Participants With Moderately Impaired Hepatic Function Compared to Healthy Participants
NCT00819468
Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase
NCT00478647
Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients
NCT00497796
Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD
NCT00500071
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 52 |
| Phase 2 | 56 |
| Phase 3 | 98 |
| Phase 4 | 20 |
What is open in the Shire pipeline
1 recruiting of 245 indexed (0% open); 212 completed (87%).
Phase mix: 118 late (III/IV) vs 108 early (I/II) (balanced across stages).
Top condition: Healthy (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Shire: open-pipeline peers nationwide
Peers matched on 245 registered trials and 0% open enrollment, not the therapeutic-area sidebar.
Shire sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 245 trials (± recruiting share)
- University of Cincinnati · 245 trials · 14% recruiting
- State University of New York at Buffalo · 243 trials · 21% recruiting
- Masonic Cancer Center, University of Minnesota · 249 trials · 14% recruiting
- University of Massachusetts, Worcester · 240 trials · 13% recruiting
Sponsors near 0% open enrollment (± trial volume)
- Gynecologic Oncology Group · 1% recruiting · 154 trials
- Mylan Pharmaceuticals · 1% recruiting · 146 trials
- Johnson & Johnson Vision Care · 1% recruiting · 142 trials
- 10xBio · 0% recruiting · 3 trials
Related
What to do with this Shire page
245 registered trials is a research-attention snapshot, not an endorsement of Shire or any single study.
- 1 of Shire's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition Shire studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Shire pipeline card: 245 registered trials from official public datasets.Report a data error.